Our company's roots in Europe go back to the 1980s, when both Daiichi and Sankyo established offices in Düsseldorf, Germany. In 1990 Sankyo acquired the Luitpold Werke in Munich, Germany, a mid-sized German pharmaceutical company with production facilities in Pfaffenhofen, Germany and Altkirch, France. In 2006, the merger between the two Japanese companies took place in Europe. Today our European headquarters are located in Munich. We currently do business in 13 European countries and Canada. Through licensing and sales agreements, our products are available in almost every European market as well as in more than 50 countries outside the EU. We invest in clinical trials and research and development in the UK.
With about 2,500 employees, we are one of the strongest Japanese pharmaceutical companies in Europe.
There are currently 212 people at Daiichi Sankyo in the UK, 52% of whom are customer facing*.
At Daiichi Sankyo UK, the National Health Service is our biggest stakeholder. That’s why we make it our business to understand the challenges faced by the four devolved nations. Variations in policy and funding are often determined by disease morbidity and mortality rates. In the south of England, for example, early deaths arising from CVD are lower than in other UK regions**.
Regional guidance from the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium and Scottish Intercollegiate Guidelines Network, and the All Wales Strategy Group has significant influence on prescribing and patient care.
Whilst we adapt our programmes to reflect the wider goals of the NHS, such as reducing the impact of CVD and diabetes, we also tailor our service to meet the local needs of our customers. This collaborative approach between the NHS and industry, supported by the Department of Health and the ABPI, enables pioneering treatments and models of care to be developed and delivered direct to patients.
*Daiichi Sankyo UK company data.
**British Heart Foundation. Heart Statistics. BHF Statistics Factsheet – UK. January 2022. Available at: https://www.bhf.org.uk/what-we-do/our-research/heart-statistics Last accessed March 2022.
To meet the needs of the evolving NHS, commercial operations at Daiichi Sankyo UK are structured into regional business units. We maintain our competitive edge by deploying our people and resources appropriately across the country, according to local or individual requirements.
We work with prescribing advisors, GPs, nurses, dispensing managers, practice managers and retail pharmacists in primary care – through to consultants, hospital doctors, nurses, business managers and pharmacists in secondary care.
With such a diverse range of customers, we train our people to the highest level to provide quality advice and information on all our products.
Highly-skilled medical liaison and medical services teams complement our sales and marketing specialists by providing essential clinical, scientific, pharmacovigilance and regulatory support to our UK customers.
DSC/23/0248 August 2023